NEW YORK, NY / ACCESSWIRE / August 8, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Didi Global Inc. F/K/A Xiaoju Kuaizhi Inc. (NYSE:DIDI)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form?prid=18330&wire=1
Lead Plaintiff Deadline: September 7, 2021
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired DiDi: (a) American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2021 initial public offering; and/or (b) securities between June 30, 2021 and July 21, 2021, inclusive.
Allegations against DIDI include that: (1) DiDi's apps did not comply with applicable laws and regulations governing privacy protection and the collection of personal information; (2) as a result, the Company was reasonably likely to incur scrutiny from the Cyberspace Administration of China; (3) the CAC had already warned DiDi to delay its IPO to conduct a self-examination of its network security; (4) as a result of the foregoing, DiDi's apps were reasonably likely to be taken down from app stores in China, which would have an adverse effect on its financial results and operations; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
CorMedix Inc. (NASDAQ:CRMD)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/cormedix-inc-loss-submission-form?prid=18330&wire=1
Lead Plaintiff Deadline: September 20, 2021
Class Period: July 8, 2020 - May 13, 2021
Allegations against CRMD include that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Zymergen Inc. (NASDAQ:ZY)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/zymergen-inc-loss-submission-form?prid=18330&wire=1
Lead Plaintiff Deadline: October 4, 2021
This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.
Allegations against ZY include that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/658874/SHAREHOLDER-ALERT-DIDI-CRMD-ZY-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
